Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Germany: Drug Spending Crack Down Could Mean Tougher Reference Pricing Measures

Executive Summary

Pricing reforms in Germany could have a ripple effect elsewhere as other countries look for inspiration on how to rein in pharmaceutical spending.

You may also be interested in...



Germany’s New Government Will Maintain Price Freeze And Slash Free Pricing Period

Big changes are in store on the drug pricing front in Germany. Further reforms could depend on who is appointed health minister.

Mexico Continues Reliance Strategy To Expand Drug Access

Mexico aims to speed up the registration of generics and biosimilars.

Belgium Aims To Drive Biologic Competition Through Tendering

New tendering rules in Belgium aim to improve competition between biosimilars and originators, for example by setting contract durations for tendering contracts and limiting the criteria for such contracts.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS145466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel